Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Thermo Fisher Scientific Inc.
Headquarters: Waltham, MA, United States of America
Website: http://www.thermofisher.com
Year Founded: 1902
Status: Public
Industry Sector: HealthTechnology
CEO: Marc N. Casper, MBA
Number Of Employees: 125,000
Enterprise Value: $226,530,082,340
PE Ratio: 31.6
Exchange/Ticker 1: NYSE:TMO
Exchange/Ticker 2: N/A
Latest Market Cap: $196,949,114,880
BioCentury | Oct 11, 2024
Management Tracks
Flagship takes on a third managing partner
Plus: New CEOs at Wheeler, Abalos, Oncovita, Syneos and Calluna, and updates from Phase, Ziphius and more
BioCentury | Sep 5, 2024
Management Tracks
Pfizer names Elif Aral president of MERA
Plus: CEO Amy Emerson steps down at Lykos, David Hough made CMO, and updates from Opthea, Modus, Melinta and more
BioCentury | Jul 24, 2024
Management Tracks
Trimarchi becomes president, COO of BridgeBio
Plus: New CEO, CFO at Beacon and updates from enGene, Broken String and Nashville
BioCentury | Jul 18, 2024
Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | Jul 12, 2024
Finance
Venture Report: With more company creation on tap, Flagship raises $3.6B
Plus: Big rounds for Element, Beacon and Myricx
BioCentury | Feb 29, 2024
Deals
In Trodelvy pact, Gilead drawing clinical expertise from Abingworth’s Launch team
With important work ahead for ADC in lung cancer, Gilead strikes co-development deal with Carlyle-owned life sciences firm
BioCentury | Jan 9, 2024
Deals
Jan. 8 Quick Takes: Novartis taps China-based Argo for RNAi deal
Plus: Venrock unveils $650M fund and more from Calypso, Isomorphic, Bayer, Flagship and Vertex
BioCentury | Oct 30, 2023
Finance
New $356M fund gives Abingworth more cash for late-stage trials
With some biopharmas strapped for cash to fund Phase III programs, PE-backed firm’s co-investment fund now supplements co-development fund
BioCentury | Oct 25, 2023
Management Tracks
Korro promoting Chappell to COO, adding Pearson to board
Plus: 3T hires Irving and updates from Q32 Bio, Garuda and Fibrocor
BioCentury | Oct 18, 2023
Management Tracks
eTheRNA names Sagaert CEO, Dekkers as chairman
Plus: Cyrus Harmon becomes CEO at Vilya, and updates from Epic Bio, Exscientia, Pliant, Cognito, Pattern
Items per page:
1 - 10 of 249